Sign In
Buy PGEN
$3.81
-0.0500 (-1.30%)
At Close: Jun 03, 2026
GERMANTOWN, Md. , March 12, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
04:05pm, Tuesday, 05'th Mar 2024
GERMANTOWN, Md. , March 5, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
04:05pm, Tuesday, 06'th Feb 2024
GERMANTOWN, Md. , Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of
Precigen: RRP Targeting With AdenoVerse Technology Platform
07:39pm, Friday, 19'th Jan 2024
FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA fi
– Designation is an important step toward bringing this potentially life-changing therapy to European patients – – EU Orphan Drug Designation is the first regulatory designation for a gorilla ad
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 08'th Jan 2024
– PRGN-2012 Phase 2 pivotal study data in RRP is anticipated in the second quarter of 2024; the Company plans to submit a BLA under an accelerated approval pathway in the second half of 2024; c
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:05pm, Monday, 18'th Dec 2023
GERMANTOWN, Md., Dec. 18, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o
5 ‘Jackpot' Stocks to Buy for 2024 for 10X Gains
03:38pm, Monday, 04'th Dec 2023
Last week, I revealed five “jackpot” stocks to buy for 2024.
Precigen to Participate in the JMP Securities Hematology and Oncology Summit
04:05pm, Wednesday, 29'th Nov 2023
GERMANTOWN, Md. , Nov. 29, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o
3 Penny Stocks to Buy to Turn $1 into $100: November 2023
02:22pm, Wednesday, 22'nd Nov 2023
In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through penny
Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
04:55pm, Thursday, 09'th Nov 2023
– Based on FDA confirmation in August 2023 that the ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal study to support BLA submission under an accelerated approval
Precigen to Participate in Upcoming Leading Investor and Industry Conferences
04:05pm, Tuesday, 19'th Sep 2023
GERMANTOWN, Md. , Sept. 19, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives
Should You Buy Precigen, Inc. (PGEN) After Golden Cross?
11:17am, Tuesday, 05'th Sep 2023
Precigen, Inc. (PGEN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PGEN's 50-day simple moving average broke out above its 200-da
10 Top Penny Stocks To Buy According To Insiders In August
12:16pm, Thursday, 17'th Aug 2023
Engaging in the world of low-cost stocks often referred to as penny stocks, is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are
Precigen, Inc. (PGEN) Q2 2023 Earnings Call Transcript
03:03pm, Wednesday, 09'th Aug 2023
Precigen, Inc. (NASDAQ:PGEN ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Exe
